Greenwich LifeSciences (GLSI) Income from Continuing Operations (2019 - 2026)
Greenwich LifeSciences' (GLSI) quarterly Income from Continuing Operations came in at 17198292.0 in Q4 2025, down 5.48% YoY from 18195559.99 in Q4 2024, and down 314.23% on a QoQ basis from 4151845.0 in Q3 2025.
Powered by 
Analysis
Greenwich LifeSciences (GLSI) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Greenwich LifeSciences (GLSI) has 7 years of Income from Continuing Operations data on file, last reported at 17198292.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 5.48% year-over-year to 17198292.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 28633777.0 (down 19.04% YoY) and the FY2025 annual result came in at 28633777.0, down 19.04% from the prior year.
- Income from Continuing Operations declined to 17198292.0 in Q4 2025, from 4151845.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 597008.0 in Q1 2021 to a low of 17198292.0 in Q4 2025.
- A 5-year average of 4433267.9 and a median of 2963537.5 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 511.25% — and 2023, when it soared 44.75%.
- Tracing GLSI's Income from Continuing Operations over 5 years: stood at 3874993.0 in 2021, then sank by 52.98% to 5927876.0 in 2022, then fell by 22.34% to 7251983.0 in 2023, then slumped by 124.83% to 16304661.0 in 2024, then fell by 5.48% to 17198292.0 in 2025.
- The last three Income from Continuing Operations figures came in at 17198292.0 (Q4 2025), 4151845.0 (Q3 2025), and 4025278.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Greenwich LifeSciences | 231.59 Mn | 231.59 Mn | - | -5.66 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -5.66 Mn |
| Dec 31, 2025 | -7.92 Mn |
| Sep 30, 2025 | -4.15 Mn |
| Jun 30, 2025 | -4.03 Mn |
| Mar 31, 2025 | -2.74 Mn |
| Dec 31, 2024 | -9.67 Mn |
| Sep 30, 2024 | -2.67 Mn |
| Jun 30, 2024 | -2.61 Mn |
| Mar 31, 2024 | -2.47 Mn |
| Dec 31, 2023 | -2.75 Mn |
| Sep 30, 2023 | -2.39 Mn |
| Jun 30, 2023 | -1.63 Mn |
| Mar 31, 2023 | -2.12 Mn |
| Dec 31, 2022 | -2.79 Mn |
| Sep 30, 2022 | -2.32 Mn |
| Jun 30, 2022 | -746,073.00 |
| Mar 31, 2022 | -1.97 Mn |
| Dec 31, 2021 | -2.36 Mn |
| Sep 30, 2021 | -863,118.00 |
| Jun 30, 2021 | -749,745.00 |